PDCD1 and neoplasm: In addition, the neoantigen fitness model described by Łuksza et al., which is based on the likelihood of neoantigen presentation by HLA molecules and subsequent T cell recognition, is able to predict clinical outcome of anti-PD-1 antibody-treated tumor patients [50].